ARCA biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting | Plans Genetically-Targeted Development of AB171 for Peripheral Arterial Disease and Heart Failure Posted on November 16, 2017 by ARCA IT - Press Release, Uncategorized AB171 Patents and Development Program - FINAL
ARCA BIOPHARMA ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Posted on November 9, 2017 by ARCA IT - Press Release, Uncategorized 2017 Q3 Financial Results and Business Update - FINAL